Cargando…

Current and Future Gene Therapy for Malignant Gliomas

Malignant gliomas are the most common neoplasm in the central nervous system. When treated with conventional treatments including surgery, irradiation, and chemotherapy, the average life expectancy of the most malignant type, glioblastoma multiforme is usually less than 1 year. Therefore, gene thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanzawa, Takao, Ito, Hideaki, Kondo, Yasuko, Kondo, Seiji
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC179758/
https://www.ncbi.nlm.nih.gov/pubmed/12686720
http://dx.doi.org/10.1155/S1110724303209013
_version_ 1782120869310496768
author Kanzawa, Takao
Ito, Hideaki
Kondo, Yasuko
Kondo, Seiji
author_facet Kanzawa, Takao
Ito, Hideaki
Kondo, Yasuko
Kondo, Seiji
author_sort Kanzawa, Takao
collection PubMed
description Malignant gliomas are the most common neoplasm in the central nervous system. When treated with conventional treatments including surgery, irradiation, and chemotherapy, the average life expectancy of the most malignant type, glioblastoma multiforme is usually less than 1 year. Therefore, gene therapy is expected to be an effective and possibly curative treatment. Many gene therapeutic approaches have demonstrated efficacy in experimental animal models. However, the current clinical trials are disappointing. This review focuses on current therapeutic genes/vectors/delivery systems/targeting strategies in order to introduce updated trends and hopefully indicate prospective gene therapy for malignant gliomas.
format Text
id pubmed-179758
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-1797582003-12-03 Current and Future Gene Therapy for Malignant Gliomas Kanzawa, Takao Ito, Hideaki Kondo, Yasuko Kondo, Seiji J Biomed Biotechnol Review Article Malignant gliomas are the most common neoplasm in the central nervous system. When treated with conventional treatments including surgery, irradiation, and chemotherapy, the average life expectancy of the most malignant type, glioblastoma multiforme is usually less than 1 year. Therefore, gene therapy is expected to be an effective and possibly curative treatment. Many gene therapeutic approaches have demonstrated efficacy in experimental animal models. However, the current clinical trials are disappointing. This review focuses on current therapeutic genes/vectors/delivery systems/targeting strategies in order to introduce updated trends and hopefully indicate prospective gene therapy for malignant gliomas. Hindawi Publishing Corporation 2003-03-19 /pmc/articles/PMC179758/ /pubmed/12686720 http://dx.doi.org/10.1155/S1110724303209013 Text en Copyright © 2003, Hindawi Publishing Corporation
spellingShingle Review Article
Kanzawa, Takao
Ito, Hideaki
Kondo, Yasuko
Kondo, Seiji
Current and Future Gene Therapy for Malignant Gliomas
title Current and Future Gene Therapy for Malignant Gliomas
title_full Current and Future Gene Therapy for Malignant Gliomas
title_fullStr Current and Future Gene Therapy for Malignant Gliomas
title_full_unstemmed Current and Future Gene Therapy for Malignant Gliomas
title_short Current and Future Gene Therapy for Malignant Gliomas
title_sort current and future gene therapy for malignant gliomas
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC179758/
https://www.ncbi.nlm.nih.gov/pubmed/12686720
http://dx.doi.org/10.1155/S1110724303209013
work_keys_str_mv AT kanzawatakao currentandfuturegenetherapyformalignantgliomas
AT itohideaki currentandfuturegenetherapyformalignantgliomas
AT kondoyasuko currentandfuturegenetherapyformalignantgliomas
AT kondoseiji currentandfuturegenetherapyformalignantgliomas